Stay ahead with our blog, your go-to source for the latest in healthcare
technology, policy, and research.
Nearly 4 million women worldwide are diagnosed with breast or gynecological cancers each year. Yet too many factors around these diseases are still poorly understood, including why there are so many disparities and variances in treatment and outcomes. Clinical trials have been helpful in illuminating some of these issues. And early approaches to
Cancer comes in many forms, including hematologic malignancies that originate in blood-forming tissues or in the cells of the immune system, and solid tumors that form as abnormal masses of tissue and are named for the type of cells and classified by the organ or biologic structure from which they originate. Hematologic cancers, such as […]
…
Using AI to transform life sciences data analysis: An early look at CAILIN’s performance COTA has launched the COTA AI Language Insights Network (CAILIN) to expedite data analytics. CAILIN is an oncology trained, on-demand insight generator designed to answer a variety of fundamental questions pertaining to data analytics, including specific cohort size, subgroup breakdowns, […]
…
NEW YORK–(BUSINESS WIRE)–COTA Inc., a leader in real-world data (RWD) and analytics for oncology, announces a new partnership with leading precision oncology company Guardant Health Inc. (Nasdaq: GH) that will allow biopharmaceutical researchers to access the combined resources of COTA’s research-grade electronic health record (EHR) data from academic and community care centers and Guardant’s clinicogenomic […]
…
Findings to be Presented at the San Antonio Breast Cancer Symposium NEW YORK, Dec. 9, 2024 /PRNewswire/ — COTA Inc., a leader in real-world data (RWD) and analytics for oncology, PreciseDx, an innovator in AI-powered digital pathology focused on oncology diagnostics, and Baptist Health South Florida today announced new study results validating the artificial intelligence […]
…
For over a decade, COTA has been tackling the most complicated cancer data to produce real-world data that can power research that will improve care and expand treatment options for patients. And now, with the integration of AI into our data curation process, we have the potential to do data-assisted clinical research with more speed […]
…
The real world is an unpredictable place. It can be messy and confusing, full of challenges and uncertainties that have to be overcome before we can move forward with confidence and clarity toward our goals. The same is true of the real-world data (RWD) generated by clinicians, health plans, medical devices, patients, and more. Before […]
…
